Use the semaglutide dosage calculator and compounded tirzepatide dosage calculator to ensure accurate dosing
Unlike some medication classes with known musculoskeletal toxicity (such as fluoroquinolone antibiotics or statins), GLP-1-based medications do not have documented effects on muscle, bone, or connective tissue that would predictably result in back pain
By simultaneously targeting amylin and GLP-1 signaling, CagriSema addresses appetite, gastric emptying, glucagon suppression, and energy homeostasis through distinct yet complementary pathways
Seek prompt medical care for any unusual or severe symptoms, such as sharp or intense pain
Once-weekly formulations like semaglutide reach steady-state concentrations after approximately 45 weeks, while dulaglutide typically reaches steady state in 24 weeks